XOMA to Present New Growth Strategy at the 2017 Wedbush PacGrow Healthcare Conference
August 09 2017 - 4:30PM
XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and
development of therapeutic antibodies, today announced that Jim
Neal, Chief Executive Officer, will present the Company’s new
strategic initiatives and value drivers at the 2017 Wedbush PacGrow
Healthcare Conference on Wednesday, August 16, 2017, at 8:35 a.m.
ET. The conference is being held at the Le Parker Meridien hotel in
New York City.
A live audio webcast of the presentation can be accessed in the
Investors section of XOMA's website at www.xoma.com. An
archived version of the webcast will be available via replay for 90
days following the presentation.
About XOMA Corporation
XOMA has an extensive portfolio of products, programs, and
technologies that are the subject of licenses the Company has in
place with other biotech and pharmaceutical companies. Many
of these licenses are the result of the Company's pioneering
efforts in the discovery and development of antibody therapeutics.
There are more than 20 such programs that are fully funded by
partners and could produce milestone payments and royalty payments
in the future. For more information, visit www.xoma.com.
Forward-Looking Statements
Certain statements contained in this press
release are forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, including statements regarding:
the potential of XOMA’s portfolio of partnered programs and
licensed technologies generating substantial milestone and royalty
proceeds over time; the significant unmet therapeutic need for
certain rare medical conditions associated with hyperinsulinism;
XOMA’s intent to license X213 and X358; and statements that
otherwise relate to future periods. These statements are based on
assumptions that may not prove accurate, and actual results could
differ materially from those anticipated due to certain risks
inherent in the biotechnology industry and for companies engaged in
the development of new products in a regulated market. Potential
risks to XOMA meeting these expectations are described in more
detail in XOMA's most recent filing on Form 10-K and in other SEC
filings. Consider such risks carefully when considering XOMA's
prospects. Any forward-looking statement in this press release
represents XOMA's views only as of the date of this press release
and should not be relied upon as representing its views as of any
subsequent date. XOMA disclaims any obligation to update any
forward-looking statement, except as required by applicable
law.
Investor contact:
Luke Heagle
Pure Communications, Inc.
+1 910-726-1372
lheagle@purecommunications.com
Media contact:
Colin Sanford
Pure Communications, Inc.
+1 415-946-1094
csanford@purecommunications.com
XOMA Royalty (NASDAQ:XOMA)
Historical Stock Chart
From Aug 2024 to Sep 2024
XOMA Royalty (NASDAQ:XOMA)
Historical Stock Chart
From Sep 2023 to Sep 2024